The neutrophil-to-lymphocyte ratio (NLR) is gaining traction as a biomarker with utility in a
variety of malignancies including melanoma. Intact lymphocyte function is necessary for …

Several studies have reported that a high neutrophil-to-lymphocyte ratio (NLR) is associated
with poor clinical outcomes in several cancers, but this ratio has not been thoroughly studied …

Background Elevated peripheral blood neutrophil-to-lymphocyte ratio (NLR) is associated
with poor oncologic outcomes in patients with stage IV melanoma and other solid tumors …

Introduction Recently, the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) has
been widely evaluated in many cancers. Here we assessed the prognostic value of …

Objectives The neutrophil–lymphocyte ratio (NLR) is an inflammatory biomarker which is
useful in cancer prognostication. We aimed to investigate the differences in baseline NLR …

Background: A number of studies have investigated the prognostic impact of the neutrophil-
to-lymphocyte ratio (NLR) in patients with melanoma but the results were controversial …

Neutrophil-to-lymphocyte ratio is a strong predictor for overall survival and disease free
survival in many cancers. Our study is the first investigation aiming to determine the …

Background In the peripheral blood, the neutrophil–lymphocyte ratio (NLR) and platelet–
lymphocyte ratio (PLR) change in response to malignancy. These biomarkers are …

Immunotherapy has revolutionized the treatment in metastatic melanoma, but alternative
biomarkers that are economical, simple and reliable still need to be clarified. In this study …

Background Previous studies have suggested that elevated neutrophil-to-lymphocyte ratio
(NLR) is prognostic for worse outcomes in patients with a variety of solid cancers, including …